Tin Chan Ngo, MD
Urology · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 2 carriers
- Offices
- 7
Offices
7 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: El Camino Health · Good Samaritan Hospital. That is not proof they admit you there this week.
Plans that list them
14 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ngo’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A105311 · Current
Licensed to practise in California · since 2008 · expires 2028-04-30 · Bowman Gray School of Medicine of Wake Forest University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$275,988
Medicare paid this office $275,988 for 516 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 292 | $46,295 | $115 |
| Diagnostic exam of bladder and urethra using an endoscope | 113 | $36,085 | $247 |
| New patient visit (45+ min) | 140 | $20,128 | $144 |
| Simple surgical subtotal removal of prostate using laparoscope | 21 | $16,905 | $805 |
| Long return visit (40+ min) | 72 | $14,955 | $170 |
See all 19 services
| Return visit (30+ min) | 292 | $46,295 | $115 |
| Diagnostic exam of bladder and urethra using an endoscope | 113 | $36,085 | $247 |
| New patient visit (45+ min) | 140 | $20,128 | $144 |
| Simple surgical subtotal removal of prostate using laparoscope | 21 | $16,905 | $805 |
| Long return visit (40+ min) | 72 | $14,955 | $170 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 18 | $11,665 | $648 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 21 | $8,635 | $345 |
| New patient visit (60+ min) | 37 | $6,956 | $188 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 15 | $5,871 | $326 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 270 | $5,306 | $15 |
| Short return visit (20+ min) | 62 | $5,224 | $80 |
| Ultrasound measurement of bladder capacity after voiding | 207 | $3,540 | $12 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 12 | $3,445 | $230 |
| Biopsy of prostate gland | 14 | $2,995 | $214 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,175 | $155 |
| Ultrasound scan of pelvic region through rectum | 14 | $1,371 | $98 |
| Simple insertion of temporary bladder tube | 11 | $1,288 | $61 |
| Review by radiologist of ureter or urethra image | 20 | $807 | $35 |
| Instillation of anti-cancer drug into bladder | 14 | $303 | $19 |
Procedures Medicare counted
| Prostate resection | 43 | More than 96% of doctors who do this |
| Removal of the uterus | 1-10 | None |
Who their Medicare patients are
516 Original Medicare patients in 2024. Average age 76 · Women 21% · Also on Medicaid 10% · Health risk score 1.06. At or below the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 70% · Coronary heart disease 32% · Chronic kidney disease 27% · Diabetes 25% · Cancer 21% · Atrial fibrillation 20% · Depression 17% · Heart failure 12% · COPD 8% · Dementia 7% · Stroke 6%.
The office billed $1,325,855, Medicare allowed $359,403 and paid $275,988; for 9,514 services of 77 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 516 | 9,514 | 76 | 1.06 | $1,325,855 | $275,988 |
| 2023 | 515 | 8,561 | 76 | 1.09 | $1,146,072 | $253,716 |
| 2022 | 534 | 10,431 | 76 | 1.13 | $1,063,886 | $234,415 |
| 2021 | 487 | 9,649 | 76 | 1.11 | $1,028,619 | $235,620 |
| 2020 | 451 | 12,485 | 76 | 1.23 | $1,097,111 | $209,507 |
| 2019 | 431 | 6,981 | 76 | 1.22 | $942,282 | $167,212 |
| 2018 | 275 | 596 | 74 | 1.55 | $422,481 | $73,057 |
| 2017 | 269 | 567 | 70 | 1.90 | $527,119 | $62,800 |
| 2016 | 210 | 470 | 71 | 1.76 | $443,893 | $53,310 |
| 2015 | 368 | 769 | 71 | 1.71 | $464,902 | $79,225 |
| 2014 | 319 | 954 | 73 | 1.38 | $365,287 | $129,754 |
| 2013 | 45 | 61 | 74 | 1.18 | $15,284 | $7,190 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 17 services
| Return visit (30+ min) | 247 | $35,768 | $115 |
| Diagnostic exam of bladder and urethra using an endoscope | 105 | $32,802 | $245 |
| New patient visit (45+ min) | 176 | $25,612 | $146 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 22 | $14,154 | $643 |
| Long return visit (40+ min) | 56 | $12,414 | $170 |
| Biopsy of prostate gland | 32 | $7,401 | $231 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 15 | $6,089 | $381 |
| Short return visit (20+ min) | 61 | $5,587 | $81 |
| Ultrasound measurement of bladder capacity after voiding | 181 | $2,955 | $11 |
| Ultrasound scan of pelvic region through rectum | 28 | $2,855 | $102 |
| New patient visit (60+ min) | 13 | $2,532 | $195 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,919 | $160 |
| Insertion of stent in ureter using an endoscope | 13 | $1,475 | $98 |
| Simple insertion of temporary bladder tube | 13 | $1,228 | $65 |
| New patient visit (30+ min) | 12 | $1,221 | $102 |
| 3d radiographic procedure with computerized image postprocessing | 17 | $860 | $51 |
| Review by radiologist of ureter or urethra image | 16 | $618 | $36 |
2022: 17 services
| Diagnostic exam of bladder and urethra using an endoscope | 99 | $34,093 | $249 |
| Return visit (30+ min) | 227 | $33,576 | $116 |
| New patient visit (45+ min) | 184 | $26,226 | $143 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 24 | $16,015 | $667 |
| Long return visit (40+ min) | 50 | $9,183 | $153 |
| New patient visit (60+ min) | 38 | $7,771 | $205 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 18 | $7,081 | $393 |
| Biopsy of prostate gland | 20 | $4,787 | $239 |
| Short return visit (20+ min) | 51 | $4,508 | $85 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 11 | $4,047 | $337 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,080 | $181 |
| Ultrasound scan of pelvic region through rectum | 22 | $3,030 | $132 |
| Ultrasound measurement of bladder capacity after voiding | 191 | $2,703 | $11 |
| Insertion of stent in ureter using an endoscope | 13 | $1,197 | $92 |
| Simple insertion of temporary bladder tube | 12 | $906 | $60 |
| 3d radiographic procedure with computerized image postprocessing | 12 | $813 | $68 |
| Review by radiologist of ureter or urethra image | 17 | $619 | $36 |
2021: 17 services
| Return visit (30+ min) | 211 | $32,490 | $119 |
| Diagnostic exam of bladder and urethra using an endoscope | 99 | $31,777 | $244 |
| New patient visit (45+ min) | 176 | $25,906 | $147 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 27 | $18,072 | $669 |
| Short return visit (20+ min) | 74 | $7,087 | $82 |
| Long return visit (40+ min) | 36 | $6,179 | $154 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 13 | $5,507 | $393 |
| New patient visit (60+ min) | 22 | $4,659 | $212 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,910 | $178 |
| Biopsy of prostate gland | 13 | $3,339 | $257 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 12 | $3,162 | $226 |
| Ultrasound scan of pelvic region through rectum | 21 | $2,215 | $105 |
| Ultrasound measurement of bladder capacity after voiding | 137 | $2,121 | $11 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $1,580 | $99 |
| Simple insertion of temporary bladder tube | 17 | $1,571 | $60 |
| Insertion of stent in ureter using an endoscope | 13 | $1,244 | $89 |
| New patient visit (30+ min) | 11 | $936 | $85 |
2020: 19 services
| New patient visit (45+ min) | 162 | $23,088 | $143 |
| Return visit (30+ min) | 184 | $21,900 | $95 |
| Diagnostic exam of bladder and urethra using an endoscope | 80 | $20,908 | $218 |
| Surgical removal of prostate and surrounding lymph nodes using an endoscope | 16 | $16,274 | $1,017 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 22 | $13,969 | $635 |
| Long return visit (40+ min) | 38 | $5,452 | $127 |
| Biopsy of prostate gland | 19 | $4,836 | $255 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 12 | $4,658 | $388 |
| Short return visit (20+ min) | 66 | $4,639 | $65 |
| Removal of lymph nodes of groin and pelvis | 11 | $4,154 | $378 |
| Telephone medical discussion with physician, 21-30 minutes | 27 | $3,029 | $104 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,315 | $178 |
| New patient visit (30+ min) | 20 | $1,959 | $98 |
| Ultrasound scan of pelvic region through rectum | 27 | $1,850 | $69 |
| Insertion of stent in ureter using an endoscope | 14 | $1,380 | $81 |
| Ultrasound measurement of bladder capacity after voiding | 99 | $1,298 | $11 |
| Simple bladder irrigation and/or instillation | 13 | $1,167 | $78 |
| Simple insertion of temporary bladder tube | 11 | $830 | $55 |
| 3d radiographic procedure with computerized image postprocessing | 12 | $482 | $40 |
2019: 20 services
| New patient visit (45+ min) | 190 | $26,525 | $140 |
| Return visit (30+ min) | 133 | $15,868 | $94 |
| Diagnostic exam of bladder and urethra using an endoscope | 64 | $13,872 | $193 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 13 | $8,680 | $668 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 21 | $8,650 | $393 |
| Short return visit (20+ min) | 70 | $5,778 | $70 |
| Surgical removal of prostate and surrounding lymph nodes using an endoscope | 11 | $5,712 | $519 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 15 | $4,296 | $269 |
| Long return visit (40+ min) | 27 | $4,175 | $135 |
| Biopsy of prostate gland | 16 | $3,832 | $239 |
| New patient visit (30+ min) | 29 | $2,713 | $94 |
| New patient visit (60+ min) | 13 | $2,370 | $182 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,211 | $184 |
| Ultrasound scan of pelvic region through rectum | 31 | $2,106 | $68 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,739 | $124 |
| Ultrasound measurement of bladder capacity after voiding | 108 | $1,734 | $13 |
| Simple insertion of temporary bladder tube | 14 | $1,308 | $62 |
| Simple bladder irrigation and/or instillation | 16 | $1,297 | $76 |
| Insertion of stent in ureter using an endoscope | 13 | $1,185 | $85 |
| Review by radiologist of ureter or urethra image | 12 | $445 | $37 |
2018: 13 services
| New patient visit (45+ min) | 85 | $12,614 | $148 |
| Return visit (30+ min) | 35 | $4,010 | $100 |
| New patient visit (30+ min) | 33 | $3,240 | $98 |
| Diagnostic exam of bladder and urethra using an endoscope | 16 | $2,631 | $164 |
| Insertion of stent in ureter using an endoscope | 16 | $2,510 | $132 |
| Short return visit (20+ min) | 24 | $2,012 | $69 |
| Return visit (30+ min) | 31 | $1,739 | $50 |
| Short return visit (20+ min) | 36 | $1,582 | $36 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,467 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,438 | $65 |
| Simple insertion of temporary bladder tube | 11 | $903 | $64 |
| Ultrasound measurement of bladder capacity after voiding | 35 | $643 | $17 |
| Diagnostic exam of bladder and urethra using an endoscope | 11 | $448 | $37 |
2017: 8 services
| Return visit (30+ min) | 109 | $9,516 | $62 |
| Short return visit (20+ min) | 86 | $4,133 | $40 |
| Diagnostic exam of bladder and urethra using an endoscope | 28 | $3,305 | $92 |
| New patient visit (45+ min) | 16 | $1,721 | $108 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,587 | $122 |
| Long return visit (40+ min) | 11 | $1,199 | $92 |
| New patient visit (30+ min) | 18 | $1,154 | $64 |
| Electronic assessment of bladder emptying | 28 | $152 | $5 |
2016: 5 services
| Return visit (30+ min) | 109 | $8,968 | $63 |
| Diagnostic exam of bladder and urethra using an endoscope | 47 | $5,772 | $100 |
| Short return visit (20+ min) | 70 | $2,752 | $36 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,579 | $121 |
| Electronic assessment of bladder emptying | 20 | $91 | $4 |
2015: 13 services
| Diagnostic exam of bladder and urethra using an endoscope | 28 | $5,427 | $181 |
| Return visit (30+ min) | 66 | $4,984 | $62 |
| Short return visit (20+ min) | 66 | $4,322 | $58 |
| New patient visit (45+ min) | 32 | $3,719 | $116 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,459 | $157 |
| Diagnostic exam of bladder and urethra using an endoscope | 29 | $3,172 | $109 |
| Short return visit (20+ min) | 66 | $3,159 | $43 |
| Simple change of bladder tube | 45 | $3,045 | $46 |
| Return visit (30+ min) | 40 | $2,992 | $71 |
| Insertion of stent in ureter using an endoscope | 12 | $1,696 | $121 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,317 | $120 |
| Ultrasonic guidance for needle placement | 11 | $324 | $29 |
| Electronic assessment of bladder emptying | 15 | $83 | $5 |
2014: 11 services
| New patient visit (45+ min) | 135 | $19,056 | $141 |
| Diagnostic exam of bladder and urethra using an endoscope | 69 | $13,536 | $183 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 16 | $11,220 | $701 |
| Return visit (30+ min) | 89 | $10,823 | $94 |
| Short return visit (20+ min) | 116 | $10,747 | $64 |
| New patient visit (30+ min) | 46 | $4,323 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,607 | $172 |
| Biopsy of prostate gland | 17 | $3,315 | $195 |
| Simple insertion of temporary bladder tube | 11 | $1,639 | $61 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,537 | $110 |
| Electronic assessment of bladder emptying | 16 | $62 | $4 |
2013: 2 services
| New patient visit (45+ min) | 19 | $2,707 | $142 |
| Return visit (30+ min) | 13 | $1,229 | $95 |
Medicaid work
$465 in 2018
Medicaid paid $465 for 127 billed services this clinician did in 2018, up to 30 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 79 | $285 |
| Return visit (30+ min) | 48 | $181 |
| 2018 | 127 | 2 | 30 | $465 |
Drugs they prescribed that Part D paid
$162,534
Pharmacies billed $162,534 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 1% of their Part D prescriptions (11 of 1,112) in 2024. At or below the middle of the specialty; the typical urology clinician is at 2%.
981 generic and 131 brand-name prescriptions · $162,534 in drug cost · 121 antibiotic prescriptions to 77 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Gemtesa | 83 | $90,667 | $1,092 |
| Myrbetriq | 31 | $29,399 | $948 |
| Tamsulosin | 368 | $7,969 | $22 |
| Xyosted | 13 | $7,387 | $568 |
| Alfuzosin Hcl Er | 142 | $3,245 | $23 |
See all 19 drugs
| Gemtesa | 83 | $90,667 | $1,092 |
| Myrbetriq | 31 | $29,399 | $948 |
| Tamsulosin | 368 | $7,969 | $22 |
| Xyosted | 13 | $7,387 | $568 |
| Alfuzosin Hcl Er | 142 | $3,245 | $23 |
| Finasteride | 131 | $2,476 | $19 |
| Testosterone | 12 | $2,363 | $197 |
| Estradiol | 13 | $1,088 | $84 |
| Potassium Citrate Er | 25 | $926 | $37 |
| Doxazosin Mesylate | 20 | $565 | $28 |
| Solifenacin | 15 | $551 | $37 |
| Dutasteride | 11 | $532 | $48 |
| Oxybutynin Chloride Er | 24 | $386 | $16 |
| Ketorolac Tromethamine | 23 | $282 | $12 |
| Sulfamethoxazole-Trimethoprim | 32 | $160 | $5 |
| Ciprofloxacin | 37 | $120 | $3 |
| Cephalexin | 30 | $107 | $4 |
| Hydrocodone-Acetaminophen | 11 | $46 | $4 |
| Sildenafil Citrate | 17 | $14 | $1 |
Year by year
| 2024 | 1,112 | 333 | 1% (11) | 12% | $162,534 |
| 2023 | 1,124 | 353 | None | None | $104,203 |
| 2022 | 993 | 335 | 2% (23) | None | $88,871 |
| 2021 | 844 | 273 | 4% (30) | None | $85,689 |
| 2020 | 773 | 247 | 5% (40) | None | $69,814 |
| 2019 | 606 | 208 | 9% (54) | 12% | $40,329 |
| 2018 | 668 | 178 | 2% (14) | 19% | $58,493 |
| 2017 | 817 | 169 | 2% (14) | 23% | $89,419 |
| 2016 | 570 | 141 | None | 13% | $36,057 |
| 2015 | 370 | 148 | 5% (18) | None | $38,595 |
| 2014 | 324 | 106 | 11% (35) | None | $39,531 |
| 2013 | 21 | 16 | None | None | $1,438 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Myrbetriq | 42 | $37,751 | $899 |
| Gemtesa | 24 | $21,276 | $886 |
| Tamsulosin | 424 | $10,873 | $26 |
| Testosterone | 15 | $6,028 | $402 |
| Alfuzosin Hcl Er | 138 | $3,980 | $29 |
| Finasteride | 125 | $2,101 | $17 |
| Oxybutynin Chloride Er | 59 | $921 | $16 |
| Ciprofloxacin | 57 | $280 | $5 |
| Ketorolac Tromethamine | 15 | $237 | $16 |
| Sulfamethoxazole-Trimethoprim | 36 | $175 | $5 |
| Cephalexin | 55 | $155 | $3 |
| Amoxicillin-Clavulanate Potass | 13 | $141 | $11 |
2022: 12 drugs
| Myrbetriq | 72 | $57,544 | $799 |
| Tamsulosin | 400 | $9,779 | $24 |
| Oxybutynin Chloride Er | 53 | $2,687 | $51 |
| Testosterone | 11 | $2,673 | $243 |
| Finasteride | 107 | $1,884 | $18 |
| Estradiol | 17 | $1,719 | $101 |
| Alfuzosin Hcl Er | 66 | $1,713 | $26 |
| Ketorolac Tromethamine | 18 | $321 | $18 |
| Ciprofloxacin | 56 | $266 | $5 |
| Cephalexin | 46 | $227 | $5 |
| Sulfamethoxazole-Trimethoprim | 48 | $182 | $4 |
| Hydrocodone-Acetaminophen | 23 | $133 | $6 |
2021: 11 drugs
| Myrbetriq | 67 | $48,875 | $729 |
| Elmiron | 11 | $10,022 | $911 |
| Tamsulosin | 335 | $7,922 | $24 |
| Oxybutynin Chloride Er | 70 | $3,390 | $48 |
| Finasteride | 88 | $1,807 | $21 |
| Potassium Citrate Er | 15 | $1,504 | $100 |
| Alfuzosin Hcl Er | 56 | $1,478 | $26 |
| Sulfamethoxazole-Trimethoprim | 34 | $151 | $4 |
| Cephalexin | 29 | $147 | $5 |
| Hydrocodone-Acetaminophen | 30 | $140 | $5 |
| Ciprofloxacin | 30 | $130 | $4 |
2020: 10 drugs
| Myrbetriq | 61 | $38,939 | $638 |
| Tamsulosin | 277 | $5,487 | $20 |
| Oxybutynin Chloride Er | 60 | $2,897 | $48 |
| Finasteride | 73 | $1,641 | $22 |
| Nitrofurantoin Mono-Macro | 13 | $1,111 | $85 |
| Alfuzosin Hcl Er | 37 | $918 | $25 |
| Cephalexin | 48 | $405 | $8 |
| Hydrocodone-Acetaminophen | 36 | $267 | $7 |
| Ciprofloxacin | 34 | $163 | $5 |
| Sulfamethoxazole-Trimethoprim | 39 | $163 | $4 |
2019: 10 drugs
| Myrbetriq | 61 | $23,806 | $390 |
| Tamsulosin | 186 | $2,822 | $15 |
| Estradiol | 14 | $2,710 | $194 |
| Oxybutynin Chloride Er | 60 | $2,370 | $39 |
| Finasteride | 71 | $1,429 | $20 |
| Alfuzosin Hcl Er | 29 | $740 | $26 |
| Hydrocodone-Acetaminophen | 53 | $347 | $7 |
| Ciprofloxacin | 26 | $151 | $6 |
| Sulfamethoxazole-Trimethoprim | 31 | $142 | $5 |
| Cephalexin | 24 | $132 | $6 |
2018: 10 drugs
| Myrbetriq | 100 | $40,729 | $407 |
| Oxybutynin Chloride Er | 113 | $3,988 | $35 |
| Tamsulosin | 154 | $2,374 | $15 |
| Potassium Citrate Er | 16 | $2,103 | $131 |
| Finasteride | 128 | $2,094 | $16 |
| Polyethylene Glycol 3350 | 29 | $548 | $19 |
| Alfuzosin Hcl Er | 12 | $195 | $16 |
| Ciprofloxacin | 18 | $80 | $4 |
| Hydrocodone-Acetaminophen | 11 | $77 | $7 |
| Sulfamethoxazole-Trimethoprim | 12 | $63 | $5 |
2017: 12 drugs
| Myrbetriq | 119 | $47,619 | $400 |
| Vesicare | 21 | $11,785 | $561 |
| Oxybutynin Chloride Er | 132 | $5,358 | $41 |
| Tamsulosin | 190 | $4,156 | $22 |
| Finasteride | 142 | $2,392 | $17 |
| Potassium Citrate Er | 14 | $1,618 | $116 |
| Tolterodine Tartrate Er | 12 | $1,362 | $114 |
| Dutasteride | 16 | $1,091 | $68 |
| Polyethylene Glycol 3350 | 17 | $341 | $20 |
| Alfuzosin Hcl Er | 15 | $207 | $14 |
| Ciprofloxacin | 11 | $68 | $6 |
| Sodium Chloride | 14 | $45 | $3 |
2016: 11 drugs
| Myrbetriq | 32 | $13,603 | $425 |
| Vesicare | 24 | $7,999 | $333 |
| Tamsulosin | 155 | $4,053 | $26 |
| Oxybutynin Chloride Er | 52 | $1,848 | $36 |
| Finasteride | 119 | $1,587 | $13 |
| Diltiazem 12hr Er | 11 | $1,568 | $143 |
| Dutasteride | 13 | $1,233 | $95 |
| Oxybutynin Chloride | 17 | $399 | $23 |
| Bicalutamide | 20 | $384 | $19 |
| Polyethylene Glycol 3350 | 14 | $210 | $15 |
| Ciprofloxacin | 20 | $107 | $5 |
2015: 12 drugs
| Myrbetriq | 27 | $17,687 | $655 |
| Vesicare | 19 | $7,886 | $415 |
| Tamsulosin | 91 | $2,875 | $32 |
| Oxybutynin Chloride Er | 22 | $1,113 | $51 |
| Finasteride | 44 | $681 | $15 |
| Oxybutynin Chloride | 17 | $568 | $33 |
| Alfuzosin Hcl Er | 26 | $549 | $21 |
| Nitrofurantoin | 12 | $450 | $37 |
| Polyethylene Glycol 3350 | 17 | $254 | $15 |
| Bicalutamide | 12 | $178 | $15 |
| Hydrocodone-Acetaminophen | 18 | $164 | $9 |
| Ciprofloxacin | 16 | $151 | $9 |
2014: 10 drugs
| Myrbetriq | 29 | $13,429 | $463 |
| Vesicare | 22 | $11,554 | $525 |
| Cialis | 16 | $4,229 | $264 |
| Tamsulosin | 62 | $1,830 | $30 |
| Oxybutynin Chloride Er | 27 | $1,510 | $56 |
| Levofloxacin | 21 | $669 | $32 |
| Oxybutynin Chloride | 19 | $529 | $28 |
| Alfuzosin Hcl Er | 16 | $270 | $17 |
| Hydrocodone-Acetaminophen | 30 | $243 | $8 |
| Cephalexin | 13 | $71 | $5 |
Money from drug and device companies
$3,005 in 2025
| 2025 | 7 | 24 | None | $3,005 |
| 2024 | 1 | 4 | None | $154 |
| 2023 | 3 | 5 | $200 | $320 |
| 2022 | 2 | 2 | $800 | $800 |
| 2020 | 2 | 2 | None | $144 |
| 2019 | 5 | 11 | $2,500 | $4,537 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Intuitive Surgical | Da Vinci Surgical System | $1,383 | 5 payments
|
| AngioDynamics | Nanoknife | $972 | 4 payments
|
| Boston Scientific | Spaceoar System | $333 | 2 payments
|
| Sumitomo Pharma America | Gemtesa | $228 | 9 payments
|
| Ferring Pharmaceuticals | Adstiladrin | $43 | 2 payments
|
| Ethicon US | Vistaseal | $29 | 1 payment
|
See all 24 published payments
| Sumitomo Pharma America | Meals · 2025-12-16 | Gemtesa | $21 |
| Sumitomo Pharma America | Meals · 2025-12-04 | Gemtesa | $32 |
| Sumitomo Pharma America | Meals · 2025-11-20 | Gemtesa | $27 |
| Sumitomo Pharma America | Meals · 2025-10-23 | Gemtesa | $21 |
| Sumitomo Pharma America | Meals · 2025-10-09 | Gemtesa | $36 |
| Ferring Pharmaceuticals | Meals · 2025-09-23 | Adstiladrin | $16 |
| Sumitomo Pharma America | Meals · 2025-09-11 | Gemtesa | $23 |
| Sumitomo Pharma America | Meals · 2025-08-21 | Gemtesa | $5 |
| Sumitomo Pharma America | Meals · 2025-07-17 | Gemtesa | $36 |
| Ethicon US | Meals · 2025-07-16 | Vistaseal | $29 |
| Intuitive Surgical | Meals · 2025-07-01 | Da Vinci Surgical System | $61 |
| Boston Scientific | Meals · 2025-06-10 | Spaceoar System | $173 |
| Intuitive Surgical | Travel · 2025-06-02 | Da Vinci Surgical System | $257 |
| Intuitive Surgical | Travel · 2025-05-15 | Da Vinci Surgical System | $19 |
| Intuitive Surgical | Travel · 2025-05-15 | Da Vinci Surgical System | $989 |
| Intuitive Surgical | Travel · 2025-05-15 | Da Vinci Surgical System | $57 |
| Sumitomo Pharma America | Meals · 2025-03-27 | Gemtesa | $27 |
| Medtronic | Meals · 2025-03-13 | Rapidvac | $18 |
| AngioDynamics | Travel · 2025-03-06 | Nanoknife | $204 |
| Ferring Pharmaceuticals | Meals · 2025-02-27 | Adstiladrin | $27 |
| Boston Scientific | Meals · 2025-02-26 | Spaceoar Vue System - 10ml | $159 |
| AngioDynamics | Meals · 2025-01-21 | Nanoknife | $16 |
| AngioDynamics | Travel · 2025-01-14 | Nanoknife | $7 |
| AngioDynamics | Travel · 2025-01-13 | Nanoknife | $745 |
See earlier years (2024, 2023, 2022, 2020, 2019)
2024: $154
| Sumitomo Pharma America | Gemtesa | $154 | 4 payments
|
2023: $320
| Intuitive Surgical | Da Vinci Sp | $200 | 1 payment
|
| Sumitomo Pharma America | Gemtesa | $91 | 3 payments
|
| Boston Scientific | Lithovue | $29 | 1 payment
|
2022: $800
| Intuitive Surgical | Da Vinci Surgical System | $750 | 1 payment
|
| Valencia Technologies | Ecoin Device Kit | $50 | 1 payment
|
2020: $144
| Endo Pharmaceuticals | Xiaflex | $125 | 1 payment
|
| Boston Scientific | General - Bph | $19 | 1 payment
|
2019: $4,537
| Intuitive Surgical | Da Vinci Surgical System | $3,315 | 3 payments
|
| NeoTract | Urolift | $729 | 4 payments
|
| Boston Scientific | General Bph | $432 | 2 payments
|
| KARL STORZ Endoscopy-America | Flex-Xc Cmos Ureteroscope 8.5 Fr X 675mm | $44 | 1 payment
|
| Dornier MedTech America | Lithotripters & Accessories | $17 | 1 payment
|
Professional record
- NPI
- 1740478775
- Licence
- CA A105311California A105311: Current · expires 2028-04-30
- Trained
- Stanford University School of Medicine, 2013
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X)
- Mailing address
- 2350 W El Camino Real Fl 2, Mountain View, CA, 94040
- NPI first listed
- 2007-10-03
- NPI last updated
- 2018-07-09
This is when the NPI record was last certified, not a medical board exam.